Pancreatic Cancer Research

ResearcherMount Sinai HospitalActive in the last 2 years

Ruijun Tian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9521-5124; OpenAlex author ID A5069877503. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 8

  1. Targeting Prolyl 3-hydroxylase 1 inhibits pancreatic cancer progression and macrophage immunity. Co-author DOI 10.1038/s41467-026-70452-w↗
  2. Inference of upstream-mutation and metabolomic-signature causality identifies prognostic biomarkers and therapeutic targets in pancreatic cancer. Co-author DOI 10.1038/s41467-026-73871-x↗
  3. Clinical functional proteomics of intercellular signalling in pancreatic cancer. Last author DOI 10.1038/s41586-024-08225-y↗
  4. MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-332350↗
  5. Functional and Clinical Proteomic Exploration of Pancreatic Cancer. Last author DOI 10.1016/j.mcpro.2023.100575↗
  6. Kindlin-2 enhances c-Myc translation through association with DDX3X to promote pancreatic ductal adenocarcinoma progression. Co-author DOI 10.7150/thno.85421↗
  7. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  8. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peiwu Huang · 4 shared papers, 2019–2025 · strength 0.61
  2. Chengmin Liu · 2 shared papers, 2023–2026 · strength 0.38
  3. Panzhu Bai · 2 shared papers, 2023–2026 · strength 0.38
  4. Ying Sun · 2 shared papers, 2023–2026 · strength 0.38
  5. Yu Shi · 3 shared papers, 2019–2025 · strength 0.34
  6. Tony R. Hunter · 3 shared papers, 2019–2025 · strength 0.34
  7. Kai Lin · 1 shared paper, 2026 · strength 0.25
  8. Feng Chen · 1 shared paper, 2026 · strength 0.25
  9. Wei Cui · 1 shared paper, 2026 · strength 0.25
  10. Hezhi Fang · 1 shared paper, 2026 · strength 0.25
  11. Yehan Zhang · 1 shared paper, 2025 · strength 0.20
  12. Yunguang Li · 1 shared paper, 2025 · strength 0.20
  13. Min Wang · 1 shared paper, 2025 · strength 0.20
  14. Dong Gao · 1 shared paper, 2025 · strength 0.20
  15. Renyi Qin · 1 shared paper, 2025 · strength 0.20
  16. Massimiliano Mazzone · 1 shared paper, 2024 · strength 0.18
  17. Yingying Tang · 1 shared paper, 2024 · strength 0.18
  18. Zhengyan Zhang · 1 shared paper, 2024 · strength 0.18
  19. Yongwei Sun · 1 shared paper, 2024 · strength 0.18
  20. Junyi Xu · 1 shared paper, 2024 · strength 0.18
  21. Christian P. Pilarsky · 1 shared paper, 2024 · strength 0.18
  22. Jing Xue · 1 shared paper, 2024 · strength 0.18
  23. Timothy R. Donahue · 2 shared papers, 2019–2021 · strength 0.14
  24. Kathleen E. DelGiorno · 2 shared papers, 2019–2021 · strength 0.14
  25. Gaoyang Liang · 2 shared papers, 2019–2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.